$1.67 Billion is the total value of RTW INVESTMENTS, LP's 46 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTCT | Sell | PTC Therapeutics Inc | $153,953,000 | +12.0% | 3,275,591 | -19.6% | 9.22% | -7.0% |
| ARWR | Sell | ARROWHEAD PHARMACEUTICALS IN | $145,773,000 | +29.1% | 7,604,225 | -8.4% | 8.73% | +7.2% |
| RGNX | Sell | Regenxbio Inc | $110,164,000 | -26.2% | 1,459,128 | -29.8% | 6.60% | -38.7% |
| SRPT | Sell | Sarepta Therapeutics Inc | $50,725,000 | -60.8% | 314,070 | -67.9% | 3.04% | -67.4% |
| ABUS | Sell | Arbutus Biopharma Corp | $38,602,000 | +2.4% | 4,084,904 | -20.9% | 2.31% | -15.0% |
| LJPC | Sell | La Jolla Pharmaceutical Co | $24,098,000 | -38.6% | 1,197,107 | -11.1% | 1.44% | -49.0% |
| SLDB | Sell | Solid Biosciences Inc | $12,376,000 | -45.6% | 262,318 | -61.2% | 0.74% | -54.8% |
| CDNA | Sell | CareDx Inc | $10,322,000 | +10.3% | 357,766 | -53.2% | 0.62% | -8.4% |
| NVTRQ | Sell | Nuvectra Corp | $5,524,000 | -29.8% | 251,329 | -34.4% | 0.33% | -41.6% |
| STIM | Sell | Neuronetics Inc | $5,049,000 | -0.1% | 157,487 | -17.1% | 0.30% | -17.3% |
| Exit | Vivus Inc 4.5 05/01/2020note 4.500% 5/0 | $0 | – | -4,000,000 | -100.0% | -0.23% | – | |
| PTE | Exit | Polarityte Inc | $0 | – | -426,670 | -100.0% | -0.72% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.